Finnish medtech startup AIATELLA raises €2M to boost stroke prevention through AI imaging

AIATELLA, a rising Finnish medtech startup, has secured €2 million in fresh funding to accelerate the development and deployment of its AI-powered cardiovascular imaging tools. The funding round, led by Nordic Science Investments and joined by Specialist VC, Harjavalta Ventures, Business Finland, and several angel investors, will support the company’s mission to transform stroke and heart disease prevention through early detection and scalable diagnostics.

About AIATELLA

• Founded in Helsinki, AIATELLA specializes in AI-driven vascular imaging technology that automates the analysis of MRI, CT, and ultrasound scans. 

• The company’s core product, Automated Image Measurement (AIM), streamlines the traditionally manual process of vascular image measurement—cutting down hours of clinician time to just minutes. This enables earlier diagnosis, helps alleviate radiologist burnout, and ensures more patients receive timely care.

• AIATELLA’s technology is already in medical approval processes across several countries including the UK, France, and the U.S., with a focus on eventually enabling vascular image analysis across the entire circulatory system. Starting with the aorta, the largest artery in the body, the company’s ambition is to expand coverage to all major blood vessels.

Investment Details

Nordic Science Investments led the round and highlighted the company’s strong clinical foundation, technological edge, and potential to redefine how cardiovascular disease is detected and managed.

“AIATELLA is tackling one of the most significant opportunities in medicine—using AI to transform radiology. They are perfectly positioned to lead the shift from outdated, manual workflows to intelligent, preventative diagnostics,” said Alexandra Gylfe, Partner at Nordic Science Investments. 

The funds will be used to conduct clinical trials, pursue medical certifications in key markets, and roll out the company’s portable screening technology. With cardiovascular diseases remaining the leading cause of death globally – and up to 80% of related fatalities being preventable – AIATELLA is poised to bring cost-effective, early detection to millions.